Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies

PURPOSE: The receptor tyrosine kinase rearranged during transfection (RET) can be oncogenically activated by gene fusions or point mutations. Multikinase inhibitors such as cabozantinib, lenvatinib and vandetanib have demonstrated activity in RET-dependent malignancies, and selective RET inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Hegde, Aparna, Andreev-Drakhlin, Alexander Y, Roszik, Jason, Huang, Le, Liu, Shuang, Hess, Kenneth, Cabanillas, Maria, Hu, Mimi I, Busaidy, Naifa L, Sherman, Steven I, Dadu, Ramona, Grubbs, Elizabeth G, Ali, Siraj M, Lee, Jessica, Elamin, Yasir Y, Simon, George R, Blumenschein, Jr, George R, Papadimitrakopoulou, Vassiliki A, Hong, David, Meric-Bernstam, Funda, Heymach, John, Subbiah, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590373/
https://www.ncbi.nlm.nih.gov/pubmed/33097651
http://dx.doi.org/10.1136/esmoopen-2020-000799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590373/
https://www.ncbi.nlm.nih.gov/pubmed/33097651
http://dx.doi.org/10.1136/esmoopen-2020-000799

Ejemplares similares